Zurück zu Projekte

18282.2 PFLS-LS

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Zusammenfassung

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Weitere Texte

Abstract

The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide|Therapy (PRRT).

Beteiligte

Alan Harris

Wirtschaftspartner

SomTheranostics Sàrl Alan Harris Chemin de Beaufort 12 1162 St-Prex VD CH

Melpomeni Fani

Kontaktperson

Melpomeni.Fani@usb.ch

Universitätsspital Basel Melpomeni Fani Petersgraben 4 4031 Basel BS CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2016-03-31
Enddatum
2018-04-30
Bewilligte Gesamtkosten
CHF 276336.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T115 Medical technology 100.0%